Ritlecitinib Therapeutic Cheat Sheet
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre …
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre … 
The medication that the FDA recently approved for the treatment of this condition inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
Various forms of alopecia affect millions of individuals worldwide and its prevalence appears to be increasing.1 Hair loss often leads to significant distress and negatively impacts quality of life. Treatment often requires a multimodal approach, and patient satisfaction is highly variable. Dermatologists have limited tools in their treatment armamentarium and may often resort to off-label use of … 